Bicocca Open Archive

Logo unimib boa
GAMBACORTI PASSERINI, CARLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 33.027
AS - Asia 17.640
EU - Europa 15.538
SA - Sud America 2.546
AF - Africa 295
Continente sconosciuto - Info sul continente non disponibili 37
OC - Oceania 30
Totale 69.113
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 32.257
SG - Singapore 6.421
CN - Cina 4.011
IT - Italia 3.120
HK - Hong Kong 2.668
VN - Vietnam 2.647
RU - Federazione Russa 2.635
DE - Germania 2.630
BR - Brasile 2.063
IE - Irlanda 1.767
SE - Svezia 1.721
UA - Ucraina 1.063
GB - Regno Unito 815
CA - Canada 562
FI - Finlandia 410
IN - India 351
FR - Francia 338
ID - Indonesia 284
KR - Corea 282
TR - Turchia 260
AR - Argentina 219
PL - Polonia 176
AT - Austria 160
BD - Bangladesh 153
MX - Messico 138
ZA - Sudafrica 137
JP - Giappone 135
NL - Olanda 133
DK - Danimarca 119
BE - Belgio 104
ES - Italia 93
IQ - Iraq 88
EC - Ecuador 75
PK - Pakistan 51
CO - Colombia 46
VE - Venezuela 44
LT - Lituania 41
MA - Marocco 37
SA - Arabia Saudita 36
BG - Bulgaria 35
CZ - Repubblica Ceca 33
EU - Europa 32
IR - Iran 31
PE - Perù 30
CH - Svizzera 26
CL - Cile 26
EG - Egitto 26
UZ - Uzbekistan 26
PY - Paraguay 23
TN - Tunisia 23
RO - Romania 22
KE - Kenya 21
AE - Emirati Arabi Uniti 19
AU - Australia 18
MY - Malesia 18
GR - Grecia 16
JO - Giordania 16
PH - Filippine 15
PT - Portogallo 15
DO - Repubblica Dominicana 14
IL - Israele 14
JM - Giamaica 13
NO - Norvegia 13
KG - Kirghizistan 12
NP - Nepal 12
AZ - Azerbaigian 11
KZ - Kazakistan 11
MU - Mauritius 11
NZ - Nuova Zelanda 11
UY - Uruguay 11
RS - Serbia 10
BO - Bolivia 9
HN - Honduras 9
TT - Trinidad e Tobago 9
CR - Costa Rica 8
ET - Etiopia 8
PS - Palestinian Territory 8
DZ - Algeria 7
LB - Libano 7
SK - Slovacchia (Repubblica Slovacca) 7
AL - Albania 6
AM - Armenia 6
SC - Seychelles 6
TH - Thailandia 6
BH - Bahrain 5
EE - Estonia 5
GT - Guatemala 5
LA - Repubblica Popolare Democratica del Laos 5
LV - Lettonia 5
OM - Oman 5
BY - Bielorussia 4
LK - Sri Lanka 4
SY - Repubblica araba siriana 4
BN - Brunei Darussalam 3
BW - Botswana 3
CI - Costa d'Avorio 3
HR - Croazia 3
LU - Lussemburgo 3
MD - Moldavia 3
MK - Macedonia 3
Totale 69.063
Salva come PNG Salva come JPEG
Città #
Ann Arbor 6.174
Singapore 3.574
Ashburn 2.749
Woodbridge 2.706
Hong Kong 2.652
Fairfield 2.295
Dublin 1.723
Houston 1.646
Frankfurt am Main 1.503
Chandler 1.489
Wilmington 1.323
Milan 1.272
Jacksonville 1.046
Seattle 947
New York 844
Ho Chi Minh City 797
Dearborn 794
Cambridge 784
Santa Clara 753
Hefei 615
Hanoi 612
Beijing 610
Dallas 584
Princeton 564
Los Angeles 544
Nanjing 318
Shanghai 296
Moscow 270
Seoul 261
Altamura 249
Lawrence 249
Chicago 241
Jakarta 238
The Dalles 234
Buffalo 216
São Paulo 209
Göttingen 188
Munich 175
Lachine 173
Guangzhou 151
San Diego 142
Boardman 129
Toronto 124
Nuremberg 119
Helsinki 106
Tokyo 103
Lissone 101
Warsaw 100
Andover 98
Nanchang 98
Vienna 98
Brussels 97
London 95
Shenyang 95
Ottawa 92
Dong Ket 91
Rome 84
Da Nang 83
Council Bluffs 82
Fremont 81
Tianjin 77
Montreal 76
Haiphong 75
Changsha 71
Rio de Janeiro 70
Salt Lake City 70
Turku 69
Hebei 68
Stockholm 68
Johannesburg 67
Orem 66
Fürstenwalde 65
Denver 64
Brooklyn 63
Chennai 63
Romola 62
Kent 61
Jinan 58
Jiaxing 57
Poplar 55
Quận Bình Thạnh 53
Atlanta 52
Lodz 52
Ha Long 51
Lappeenranta 50
Biên Hòa 49
Hải Dương 49
Boston 48
Falls Church 48
Ninh Bình 48
Pune 47
Mexico City 46
Norwalk 46
Phoenix 46
Kocaeli 45
Curitiba 43
Kunming 42
Mountain View 42
Vũng Tàu 42
San Jose 41
Totale 46.351
Salva come PNG Salva come JPEG
Nome #
Single-center study on SARS-CoV-2 infection in patients affected by CML: Vaccination status and bosutinib therapy as possible protective factors for hospitalization 616
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways 513
Characterization of intra-host SARS-CoV-2 variants improves phylogenomic reconstruction and may reveal functionally convergent mutations 506
VERSO: a comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples 460
A bioinformatics procedure to identify and annotate somatic mutations in whole-exome sequencing data 447
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 439
CNS relapse risk in HIV-positive patients affected by DLBCL and HGBL – a retrospective study of the musthal cohort 434
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene 407
Acute myeloid leukaemia niche regulates response to L-asparaginase 406
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study 403
Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma 402
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 399
RNA-seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients 395
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib 385
OncoScore: A novel, Internet-based tool to assess the oncogenic potential of genes 383
Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years 381
Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions 380
VERSO: a comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples 380
ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine 377
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency 371
Evaluating the performance of large language models in haematopoietic stem cell transplantation decision-making 368
The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis 361
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization 361
ETNK1 MUTATIONS INCREASE MITOCHONDRIAL ACTIVITY AND PROMOTE DNA DAMAGE THROUGH ROS PRODUCTION 360
ETNK1 mutations in atypical chronic myeloid leukemia induce a mutator phenotype that can be reverted with phosphoethanolamine 360
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub 359
ETNK1 mutations promote ROS production and DNA damage through increased mitochondrial activity 357
WHOLE-EXOME SEQUENCING OF A PHILADELPHIA NEGATIVE CHRONIC MYELOID LEUKEMIA PATIENT THROUGH THE EXON-CAPTURE TECHNIQUE 355
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 352
Erratum: OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes 352
A computational procedure to identify and annotate somatic mutations in next-generation sequencing data 349
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 347
Imatinib long term effects study: three years of follow-up and assessment 336
Characterization of compound 584, an Abl kinase inhibitor with lasting effects 329
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 320
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma 318
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 313
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib 312
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia 310
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 309
Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia 306
Chronic myeloid leukemia: Second-line drugs of choice 306
BCR-ABL nuclear entrapment kills human CML cells: Ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B 304
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells 304
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia 303
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 302
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells 301
Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL) 293
Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors 292
Response to ‘D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients’ by leguay et al 286
Integrating mutational profiles and transcriptional data with ASTUTE to elucidate the key molecular functions involved in the pathogenesis of cancer 285
Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors 283
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition 282
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 282
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma 280
Inhibition of RET tyrosine kinase by SU5416 280
A fatal case of TEMPI syndrome, refractory to proteasome inhibitors and autologous stem cell transplantation 280
CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data 278
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 278
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation 277
A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036 277
Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy 276
Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases 276
Idiopathic erythrocytosis: a germline disease? 275
Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex 273
Whole-Exome Sequencing Data - Identifying Somatic Mutations 273
Integrated Analysis of Whole-Exome Sequencing and Micrornas Expression in Blast Crisis Transformation of Chronic Myeloid Leukemia 272
Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy 271
ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells 269
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients 269
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies 268
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors 268
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase 268
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 268
Evidence for D276G and L364I Bcr-Abl mutations in Ph plus leukaemic cells obtained from patients resistant to Imatinib 267
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants 267
Dissection of the RET/ß-catenin interaction in the TPC1 thyroid cancer cell line 262
Gene expression signature of non-involved lung tissue associated with survival in lung adenocarcinoma patients 260
The ALK gene, an attractive target for inhibitor development 259
Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling 256
ALK inhibitors for clinical use in cancer therapy 255
Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia 254
Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors 254
Oncoscore, a Novel, Internet-Based Tool to Assess the Oncogenic Potential of Genes Can Differentiate Between CP-CML and BC-CML Associated Genes, and Between CP-CML Patients with Good and Bad Prognosis 254
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias 253
In Vitro and in Vivo Characterization of Bosutinib as Substrate of the Pglycoprotein Efflux Transporter 252
Reply to P. Laneuville et al 251
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation 249
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis 249
BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients 248
FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery 248
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients 248
Increased sFLT-1/PlGF ratio in COVID-19: A novel link to angiotensin II-mediated endothelial dysfunction 248
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells 244
Erratum: Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design (Journal of Medicinal Chemistry (2017) 60:22 (9205-9221) DOI: 10.1021/acs.jmedchem.7b01039) 244
Remission of low-grade lymphomatoid granulomatosis with extensive pulmonary involvement following immune restoration via antiretroviral therapy in a newly diagnosed HIV patient 240
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes 239
Highly sensitive mutations detection in BCR-ABL positive leukemia prior and during imatinib treatment 237
Recurrent KIT D816V Mutation in Atypical Chronic Myeloid Leukemia 237
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy 237
Totale 31.429
Salva come PNG Salva come JPEG
Categoria #
all - tutte 232.040
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 232.040
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20214.493 0 0 0 0 0 687 780 698 650 650 473 555
2021/20224.093 331 406 499 279 276 366 213 228 206 304 329 656
2022/20236.561 864 1.919 566 554 469 932 72 333 418 126 152 156
2023/20245.361 129 146 202 235 671 1.456 978 159 443 287 90 565
2024/202513.373 790 1.498 734 665 1.115 506 914 419 1.112 1.954 1.217 2.449
2025/202617.093 4.223 2.279 2.407 3.481 3.379 1.324 0 0 0 0 0 0
Totale 70.916